Company intelligence / Profile preview

Auregen BioTherapeutics

Ownership: Private
Development stage: Other

Overview

Auregen’s lead product AUR-201—a human ear replacement built from an autologous cell line—is entering clinical trials for microtia. The company aims to provide life-like and long-lasting solutions for patients with serious medical conditions involving missing or dysfunctional tissues. No published clinical results yet; first indication rapidly moving forward in development.

Therapeutic areas: Rare DiseasesOther
Modalities: Cell therapyTissue engineering (specifically autologous cell-based tissue replacement)3D bioprinting
Industry: Biotech

Beyond the preview

Go deeper on Auregen BioTherapeutics.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Auregen BioTherapeutics.

Explore the full profile